Oxford-based Genomics keeps Vertex on board for another four years, potential $220M deal

U.S. biotech Vertex Pharmaceuticals has extended its drug discovery partnership with Oxford-based Genomics Limited by an additional four years in a deal the U.K. company says could exceed $220 million (€200 million).

ADVERTISEMENT

Why it matters: Vertex is paying for human genetic evidence that can point it to novel drug targets with improved odds of success.

“Our unique platform and our proprietary algorithms allow us to bring the full power of human genetics to understand key biological processes driving disease and to use those insights to find novel targets and powerful biomarkers,” Peter Donnelly, Genomics’ co-founder and chief executive, said in a press release. “Extending this partnership allows us to scale that approach and accelerate the delivery of novel, precision medicines for patients who need them most.”

Across the industry, failure drives most of the cost of drug development. A 2024 analysis in Nature estimated that drug targets with human genetic support for the disease being treated were 2.6 times as likely to progress from Phase 1 to launch as those without it.

Zoom in: Genomics, a 2014 University of Oxford spin-out, has spent a decade collecting, cleaning and standardizing genetic data into what it calls the world’s largest and most diverse database linking human genotypes to traits. Its Mystra platform builds on a core collection of more than 45,000 genome-wide association studies (GWAS), which scan many people’s genomes for variants linked to a disease or trait.

Genomics put the total potential contract value at more than $220 million, for research, development, regulatory and commercial milestones and tiered royalties on future net sales. The partners have not said whether the extension includes an upfront payment or research funding, or which diseases it covers. Neither company responded to requests for comment by the time the article was published.

Backstory: The companies signed the original deal in August 2018: a three-year collaboration, extendable to five years. Vertex agreed to pay for its partner’s work, as well as milestones and royalties on novel targets from the collaboration that are taken through clinical development. It also led Genomics’ £25 million (€28 million at the time) Series B round, announced at the same time as the collaboration, contributing £10.5 million (€11.7 million).

The partners extended the deal by two years in 2021, and by another three in 2024. The 2024 extension added therapeutic areas and work on identifying patient populations and on biomarkers that can show early in a trial whether a drug works.

The big picture: Other drugmakers are paying for similar target discovery. In September, Germany’s Boehringer Ingelheim expanded its kidney-disease target-discovery deal with Variant Bio, a Seattle genomics company, into cardiovascular disease. Variant said the total deal value could exceed $250 million (€219 million at the time). Novartis and GSK have signed target-discovery deals with London-based Relation Therapeutics, an early adopter of Genomics’ Mystra AI (the platform’s agentic interface).

Reality check: So far, the partners have said little about the results of their collaboration. In 2024, Donnelly said in a press release that the partners had “discovered novel genetically-validated targets,” and Genomics says it has identified more than 100 drug targets across its work, for diseases such as cancer, heart disease and diabetes. Neither company has said how many came from their collaboration or whether any has entered development.

What’s next: Those who have high hopes for the partnership include the U.K. government. “Genome science is transforming how we treat and beat disease,” Chris McDonald, the science minister, said in the press release. “Using information which is embedded in our DNA, Genomics and Vertex are able to use that data to identify promising new drugs and treatments.” The question over the next four years is whether a target from the collaboration shows up in Vertex’s clinical pipeline.

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!